OUR TECHNOLOGY
Designing Potent Immuno-therapeutics with Recombinant Nanovesicles
- Recombinant nanovesicles are derived from microbial membranes and transport payloads of biochemicals such as nucleic acids, toxins, peptides, etc. to modify a target cell’s activity.
- Nanovesicles can be engineered to carry precise payloads and attach surface proteins to direct the vesicles to specific cells.
- Derived from genetically engineered probiotics as a technology platform for the targeted delivery of vaccines and immuno-therapeutics.
- By genetically engineering the surface display of receptors and antigens, we can exquisitely target specific diseases, which enable potent protection against a range of strains.
- These designer vesicles can also be used with a time-release formulation that enables long acting dosing and reduces the number of administrations. You can read more about the research from Cornell University Professors David Putnam and Matthew DeLisa.
Universal Influenza Vaccine
We are a clinical stage company leveraging nature’s nano-vesicles
to construct an influenza A vaccine candidate, VT-105, that provides robust and durable immunity against multiple influenza strains in preclinical studies. Our lead clinical vaccine candidate addresses the need for improved, effective universal influenza A vaccines to prevent influenza and other emerging infectious diseases.
Due to the changeable nature of the influenza virus, current commercial vaccines must be made yearly. This results in less potent vaccines which do not adequately address seasonal strain variation or the emergence of new pandemic influenza variants or other infectious diseases.
Versatope displays proteins of multiple strains of influenza virus on a single nano-vesicle for a more effective and potent vaccine.
Our current influenza vaccine candidate received Investigational New Drug (IND) allowance. You can read more about this vaccine featured on the Versatope News page.